Seeking Alpha·Sep 16, 2026
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptBioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs remains a pre-commercial biotechnology entity whose valuation is entirely dependent on the successful advancement of its azelaprag clinical program. While the company has successfully bolstered its equity base to $379.1 million as of 2026Q1, it con...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.58+4.5% vs -$0.61 | $2M+63.7% vs $1M |
Q2 2026 May 8, 2026 | -$0.52+18.7% vs -$0.64 | $3M+155.9% vs $1M |
Q2 2026 May 5, 2026 | -$0.52+18.7% vs -$0.64 | $3M+155.9% vs $1M |
Q2 2026 Mar 24, 2026 | -$0.72+13.3% vs -$0.83 | $3M+119.9% vs $1M |
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).
BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.
Benchmark BIOA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioAge Labs Inc. (BIOA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.89 | $297.06M | -3.52 | — | -896.11% | -27.09% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $99.97 | $6.51B | 29.32 | 0.5% | 17.69% | 23.27% | — | |
| $98.24 | $6.74B | -31.59 | 45.83% | -85.59% | -80.48% | — | |
| $5.04 | $303.08M | -1.35 | 8.72% | -127.41% | -84.95% | — |
BioAge Labs Inc. (BIOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioAge Labs Inc. (BIOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 12, 2026·SEC
May 8, 2026·SEC
Get notified when BIOA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioAge Labs Inc. (BIOA) stock FAQ — growth, dividends, profitability & financials explained
BioAge Labs Inc. (BIOA) reported $10.4M in revenue for fiscal year 2025.
BioAge Labs Inc. (BIOA) reported a net loss of $94.5M for fiscal year 2025.
BioAge Labs Inc. (BIOA) has a return on equity (ROE) of -27.1%. Negative ROE indicates the company is unprofitable.
BioAge Labs Inc. (BIOA) had negative free cash flow of $88.1M in fiscal year 2025, likely due to heavy capital investments.
